Skip to main content

Table 7 Results of network meta-analysis of FVC (L) absolute change from baseline

From: A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials

Warfarin

-0.03 (-0.18,0.12) ⊕⊕⊝⊝low2,4

Imatinib

        

-0.04 (-0.14,0.06) ⊕⊕⊕⊝moderate2

-0.01 (-0.13,0.11) ⊕⊕⊕⊕high

Placebo

       

-0.04 (-0.37,0.29) ⊕⊕⊝⊝low2,4

-0.01 (-0.35,0.33) ⊕⊕⊕⊝moderate4

-0.00 (-0.32,0.32) ⊕⊕⊕⊕high

Macitentan

      

-0.08 (-0.26,0.10) ⊕⊕⊝⊝low2,4

-0.05 (-0.24,0.14) ⊕⊕⊕⊝moderate4

-0.04 (-0.19,0.11) ⊕⊕⊕⊕high

-0.04 (-0.39,0.31) ⊕⊕⊕⊝moderate4

Bosentan

     

-0.10 (-0.25,0.05) ⊕⊝⊝⊝ very low1,2,4

-0.07 (-0.24,0.10) ⊕⊝⊝⊝ very low1,2,4

-0.06 (-0.17,0.05) ⊕⊕⊝⊝ low1,2

-0.06 (-0.40,0.28) ⊕⊝⊝⊝ very low1,2,4

-0.02 (-0.21,0.17) ⊕⊝⊝⊝ very low1,2,4

N-acetylcysteine

    

-0.12 (-0.22,-0.02) ⊕⊕⊝⊝low2,4

-0.09 (-0.22,0.03) ⊕⊕⊕⊝moderate4

-0.08 (-0.12,-0.04) ⊕⊕⊕⊕high

-0.08 (-0.40,0.24) ⊕⊕⊕⊝moderate4

-0.04 (-0.19,0.11) ⊕⊕⊕⊝moderate4

-0.02 (-0.14,0.10) ⊕⊝⊝⊝ very low1,2,4

Nintedanib

   

-0.14 (-0.31,0.04) ⊕⊕⊝⊝low2,4

-0.10 (-0.29,0.08) ⊕⊕⊕⊝moderate4

-0.09 (-0.24,0.05) ⊕⊕⊕⊕high

-0.09 (-0.44,0.25) ⊕⊕⊕⊝moderate4

-0.05 (-0.26,0.15) ⊕⊕⊕⊝moderate4

-0.04 (-0.22,0.15) ⊕⊝⊝⊝ very low1,2,4

-0.01 (-0.16,0.13) ⊕⊕⊕⊝moderate4

GLPG1690

  

-0.17 (-0.32,-0.01) ⊕⊝⊝⊝very low1,2,4

-0.14 (-0.31,0.03) ⊕⊕⊝⊝low1,4

-0.13 (-0.25,-0.01) ⊕⊕⊕⊝moderate1

-0.13 (-0.47,0.21) ⊕⊕⊝⊝low1,4

-0.09 (-0.28,0.10) ⊕⊕⊝⊝low1,4

-0.07 (-0.23,0.10) ⊕⊝⊝⊝ very low2,3,4

-0.05 (-0.17,0.08) ⊕⊕⊝⊝low1,4

-0.03 (-0.22,0.15) ⊕⊕⊝⊝low1,4

PRM151

 

-0.24 (-0.48,-0.00) ⊕⊕⊝⊝low2,4

-0.21 (-0.46,0.04) ⊕⊕⊕⊝moderate4

-0.20 (-0.42,0.02) ⊕⊕⊕⊕high

-0.20 (-0.59,0.19) ⊕⊕⊕⊝moderate4

-0.16 (-0.42,0.10) ⊕⊕⊕⊝moderate4

-0.14 (-0.39,0.11) ⊕⊝⊝⊝very low1,2,4

-0.12 (-0.34,0.10) ⊕⊕⊕⊝moderate4

-0.11 (-0.36,0.15) ⊕⊕⊕⊝moderate4

-0.07 (-0.32,0.18) ⊕⊕⊝⊝low1,4

Pamrevlumab

  1. Data are MD(95%Cl)
  2. 1:Certainty lowered for imprecision
  3. 2:Certainty lowered for individual study risk of bias
  4. 3:Certainty lowered two levels for imprecision
  5. 4:Certainty lowered for indirectness
  6. GRADE Working Group grades of evidence – High quality: Further research is very unlikely to change our confidence in the estimate of effect; Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; Very low quality: We are very uncertain about the estimate
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us